Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mesalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 1.00 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesalamine SCHEMBL29354798 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL28077836 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL31297 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL2680203 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL6517036 | 0.98 | MEN1 (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL15329203 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL2679950 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL2680533 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL9688231 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Mesalamine SCHEMBL10493008 | 0.98 | KDM4E (0.96) | KDM4EALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108653272-B | Application of artemisinin derivatives in preparation of medicines for treating inflammatory bowel diseases | 中国科学院上海药物研究所 | 2022-09-20 | — | — | CN | disclosed |
| US-20220118170-A1 | SYSTEMS, APPARATUS, AND METHODS FOR ADMINISTERING A SUBSTANCE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-21 | — | — | US | disclosed |
| US-11185626-B2 | Systems, apparatus, and methods for administering a substance | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3603633-B1 | MEDICAL USE OF ARTEMISININ DERIVATIVE FOR TREATING INFLAMMATORY BOWEL DISEASE | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-06-16 | — | — | EP | disclosed |
| EP-3603633-A1 | MEDICAL USE OF ARTEMISININ DERIVATIVE FOR TREATING INFLAMMATORY BOWEL DISEASE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-20200030284-A1 | MEDICAL USE OF ARTEMISININ DERIVATIVE FOR TREATING INFLAMMATORY BOWEL DISEASE | JIANGSU ZUOYOU MEDICINE CO., LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-10272241-B2 | Methods for modulating autophagy using remote ischemic conditioning | THE HOSPITAL FOR SICK CHILDREN (CA) | 2019-04-30 | — | — | US | disclosed |
| CN-105025888-B | Enteric coatel tablets | 志瑞亚新药工业株式会社 | 2018-10-12 | — | — | CN | disclosed |
| US-20180055991-A1 | SYSTEMS, APPARATUS, AND METHODS FOR ADMINISTERING A SUBSTANCE | THE GENERAL HOSPITAL CORPORATION | 2018-03-01 | — | — | US | disclosed |
| CN-107207618-A | Fused polypeptide comprising GLP and immunoglobulin heterozygosis FC and application thereof | 格纳西尼有限公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2006019960-A1 | COLOSTRUM-BASED TREATMENT FOR IRRITABLE BOWEL SYNDROME | NUTRITIONAL BIOSCIENCE LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060013889-A1 | Colostrum-based treatment for irritable bowel syndrome | NUTRITIONAL BIOSCIENCE LIMITED (GB) | 2006-01-19 | — | — | US | disclosed |
| WO-2005067644-A2 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6897205-B2 | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet | ROEHM GMBH & CO. KG (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20050053660-A1 | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet | ROEHM GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20030152627-A1 | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet | ROEHM GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1248599-A1 | MULTI-PARTICULATE FORM OF MEDICAMENT, COMPRISING AT LEAST TWO DIFFERENTLY COATED FORMS OF PELLET | Röhm GmbH & Co. KG (DE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002060415-A1 | MULTI-PARTICULATE FORM OF MEDICAMENT, COMPRISING AT LEAST TWO DIFFERENTLY COATED FORMS OF PELLET | Röhm GmbH & Co. KG (DE) | 2002-08-08 | — | — | WO | disclosed |
| US-6326364-B1 | BACTERICIDES | CEDARS-SINAI MEDICAL CENTER | 2001-12-04 | — | — | US | disclosed |
| WO-2001068057-A1 | USE OF A COPOLYMER FOR PRODUCING A PHARMACEUTICAL PRODUCT FOR THE THERAPY OF ULCERATIVE COLITIS, AND PHARMACEUTICAL PRODUCT PROVIDED FOR THE INVENTIVE USE | Röhm GmbH & Co. KG (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030284-A1 | MEDICAL USE OF ARTEMISININ DERIVATIVE FOR TREATING INFLAMMATORY BOWEL DISEASE | MYD88, THPO, IL6 | PTGS2 6/4885ALOX5 112/4885KDM4E 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.